16
Participants
Start Date
May 18, 2016
Primary Completion Date
November 16, 2019
Study Completion Date
November 16, 2019
tocilizumab
subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
Collaborators (1)
Brigham and Women's Hospital
OTHER
Genentech, Inc.
INDUSTRY
Massachusetts General Hospital
OTHER